1 Hatakeyama S. TRIM proteins and cancer. NAT REV CANCER. 2011.
2 A 4-Gene Signature Predicts Survival of Patients With Resected Adenocarcinoma of the Esophagus, Junction, and Gastric Cardia.; 139(6):1995-2147483647.
3 Leong PWF, Liew K, Lim W and Chow VTK. Differential Display RT–PCR Analysis of Enterovirus-71-Infected Rhabdomyosarcoma Cells Reveals mRNA Expression Responses of Multiple Human Genes with Known and Novel Functions.; 295(1):147-159.
4 High‐resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. GENE CHROMOSOME CANC. 2008; 47(6):500-509.
5 Boutou E, Matsas R and Mamalaki A. Isolation of a mouse brain cDNA expressed in developing neuroblasts and mature neurons. Brain Research Molecular Brain Research. 2001; 86(1-2):153-167.
6 Yang B, Wang J, Wang Y, Zhou H, Wu X, Tian Z and Sun B. Novel Function of Trim44 Promotes an Antiviral Response by Stabilizing VISA. J IMMUNOL.; 190(7):3613-3619.
7 Urano T, Usui T, Takeda S, Ikeda K, Okada A, Ishida Y, Iwayanagi T, Otomo J, Ouchi Y and Inoue S. TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochemical & Biophysical Research Communications.; 383(2):268.
8 Weissman AM. Regulating protein degradation by ubiquitination. 1997; 18(4):189-198.
9 Toby GG, Gherraby W, Coleman TR and Golemis EA. A Novel RING Finger Protein, Human Enhancer of Invasion 10, Alters Mitotic Progression through Regulation of Cyclin B Levels. Molecular & Cellular Biology. 2003; 23(6):2109-2122.
10 Xiong D, Jin C, Ye X, Qiu B, Jianjun X, Zhu S, Xiang L, Wu H and Yongbing W. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway. CANCER SCI. 2018; 109(10):3080-3092.
11 Xing Y, Meng Q, Chen X, Zhao Y, Liu W, Hu J, Xue F, Wang X and Cai L. TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway. Oncotarget.; 7(21).
12 Zhang C, Liu LX, Dong ZR, Shi GM, Cai JB, Zhang PF, Ke AW, Yu JX, Zhou J and Fan J. Up-regulation of 14-3-3zeta expression in intrahepatic cholangiocarcinoma and its clinical implications. Tumour Biol. 2015; 36(3):1781-1789.
13 Ong CA, Shannon NB, Ross-Innes CS, O'Donovan M, Rueda OM, Hu DE, Kettunen MI, Walker CE, Noorani A, Hardwick RH, Caldas C, Brindle K and Fitzgerald RC. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. 2014; 106(5).
14 Luo Q, Lin H, Ye X, Huang J, Lu S and Xu L. Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway..
15 Kashimoto K, Komatsu S, Ichikawa D, Arita T and Otsuji E. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. CANCER SCI. 2012; 103(11):2021-2026.
16 Hidetaka K, Kotaro A, Kazuhiro I, Ikuko S, Keiichi K, Takeshi F, Akihiko O, Toshiaki S, Kuniko H and Satoshi I. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling. INT J MOL SCI.; 18(9):1931.
17 Kawaguchi T, Komatsu S, Ichikawa D, Hirajima S, Nishimura Y, Konishi H, Shiozaki A, Fujiwara H, Okamoto K and Tsuda H. Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma. Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine.; 39(6):568835656.
18 Li P, Yin H, Meng F, Liu S and Ma R. High TRIM44 expression in endometrial carcinoma is associated with a poorer patient outcome. Pathology - Research and Practice. 2018; 214(5).
19 Shuang L, Hexuan Y, Hongying J, Jiaqi Z and Rong M. Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer. EXP THER MED..
20 Liu S, Meng F, Ding J, Ji H, Lin M, Zhu J and Ma R. High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer. BIOSCIENCE REP..
21 Peng R, Zhang PF, Zhang C, Huang XY, Ding YB, Deng B, Bai DS and Xu YP. Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med. 2018; 7(3):796-808.
22 Wang H, Zi-Ling F, Gong-Hao Z and Xin M. <em>TRIM44</em>, a crucial target of miR-410, functions as a potential oncogene in osteosarcoma. Oncotargets & Therapy.; Volume 11:3637-3647.
23 Wei C, Wang L, Zhu M, Deng X, Wang D, Zhang S, Ying J, Yuan X, Wang Q and Xuan T. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4. J EXP CLIN CANC RES.; 38(1).
24 Yamada Y, Takayama K, Fujimura T, Ashikari D, Obinata D, Takahashi S, Ikeda K, Kakutani S, Urano T and Fukuhara H. A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. CANCER SCI..
25 Zhu X, Wu Y, Miao X, Li C, Yin H, Yang S, Lu X, Liu Y, Chen Y, Shen R, Chen X and He S. High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma. Tumour Biol. 2016; 37(11):14615-14628.
26 Raboy B, Parag HA and Kulka RG. Conjugation of [125I]ubiquitin to cellular proteins in permeabilized mammalian cells: comparison of mitotic and interphase cells. EMBO J.; 5(5):863-869.
27 Wilkinson KD, Urban MK and Haas AL. Ubiquitin is the ATP-dependent Proteolysis Factor I of rabbit reticulocytes. J BIOL CHEM. 1980; 255(16):7529-7532.
28 Fiore PPD, Polo S and Hofmann K. Opinion: When ubiquitin meets ubiquitin receptors: a signalling connection.; 4(6):491-497.
29 Varshavsky A. The ubiquitin system.; 22(10):383-387.
30 Burger and M. A. A Novel RING-Type Ubiquitin Ligase Breast Cancer-Associated Gene 2 Correlates with Outcome in Invasive Breast Cancer. CANCER RES.; 65(22):10401-10412.
31 Shabbeer S, Omer D, Berneman D, Weitzman O, Alpaugh A, Pietraszkiewicz A, Metsuyanim S, Shainskaya A, Papa MZ and Yarden RI. BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation. ONCOGENE.; 32(42):5005-5016.
32 Ryu YS, Lee Y, Lee KW, Hwang CY, Maeng JS, Kim JH, Seo YS, You KH, Song B and Kwon KS. TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF?)-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP). J BIOL CHEM.; 286(29):25729-25738.
33 Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, Ishida N, Hatakeyama S, Bessho Y, Kageyama R, Suda T and Nakayama KI. Mouse Fbw7/Sel-10/Cdc4 Is Required for Notch Degradation during Vascular Development. J BIOL CHEM.; 279(10):9417-9423.
34 Nisole S, Stoye JP and Sa B A. TRIM family proteins: retroviral restriction and antiviral defence.; 3(10):799-808.
35 Di K, Linskey ME and Bota DA. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. ONCOGENE.; 32(42):5038-5047.
36 Ozato K, Shin D, Chang T and Morse HC. TRIM family proteins and their emerging roles in innate immunity. NAT REV IMMUNOL.; 8(11):849-860.
37 McNab FW, Rajsbaum R, Stoye JP and Garra AO. Tripartite-motif proteins and innate immune regulation.; 23(1):46-56.
38 Urano T, Usui T, Takeda S, Ikeda K, Okada A, Ishida Y, Iwayanagi T, Otomo J, Ouchi Y and Inoue S. TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochemical & Biophysical Research Communications.; 383(2):268.
39 Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy. J Natl Cancer Inst.; 106(5):u50.
40 Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, Belarmino J, Van De Water L, Mian BM and Melendez JA. Manganese Superoxide Dismutase Enhances the Invasive and Migratory Activity of Tumor Cells. CANCER RES.; 67(21):10260-10267.
41 Acloque H, Adams MS, Fishwick K, Nieto MA and Bronner-Fraser M. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. CELL. 2009; 119(6):871.
42 Jou J and Diehl AM. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J CLIN INVEST.; 120(4):1031-1034.
43 Williams GH and Kai S. The cell cycle and cancer. P NATL ACAD SCI USA. 2012; 226(2):352-364.
44 Zeisberg M and Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J CLIN INVEST.; 119(6):1429-1437.
45 Fillies T, Woltering M, Brandt B, Van Diest J, Werkmeister R, Joos U and Buerger H. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. ONCOL REP.; 17(2):355-359.
46 Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL and Eldeiry WS. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21. 1997; 389(6647):187-190.
47 Zhou X, Yang Y, Ma P, Wang N, Yang D, Tu Q, Sun B, Xiang T, Zhao X and Hou Z. TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway..
48 Yu H, Kortylewski M and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. NAT REV IMMUNOL.; 7(1):41-51.
49 Yu C, Meyer D, Campbell G, Larner A, Carter-Su C, Schwartz J and Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. SCIENCE.; 269(5220):81-83.
50 Kortylewski M and Yu H. Stat3 as a Potential Target for Cancer Immunotherapy. J IMMUNOTHER.; 30(2):131-139.
51 Pineda CT and Potts PR. Oncogenic MAGEA-TRIM28 ubiquitin ligase downregulates autophagy by ubiquitinating and degrading AMPK in cancer. AUTOPHAGY.; 11(5):844-846.
52 Dong L, Sun L, Zhang X, Pan L, Lian L, Chen Z and Zhong D. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. ACTA PHARMACOL SIN. 2013; 34(2):314-318.
53 Santamaria PG and Nebreda AR. Deconstructing ERK Signaling in Tumorigenesis. MOL CELL. 2010; 38(1):3-5.
54 Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor β–induced apoptosis. HEPATOLOGY. 2009; 49(6).
55 Huang X, Ke A, Shi G, Zhang X, Zhang C, Shi Y, Wang X, Ding Z, Xiao Y and Yan J. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. HEPATOLOGY.; 57(6):2235-2247.
56 Deng X, Xiao L, Lang W, Gao F, Ruvolo P and May WJ. Novel role for JNK as a stress-activated Bcl2 kinase. J BIOL CHEM. 2001; 276(26):23681-23688.
57 Wei and C. M. Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death. SCIENCE.; 292(5517):727-730.
58 Lai Y, Lin VTG, Zheng Y, Benveniste EN and Lin F. The Adaptor Protein TRIP6 Antagonizes Fas-Induced Apoptosis but Promotes Its Effect on Cell Migration. MOL CELL BIOL. 2010; 30(23):5582-5596.
59 Bentires-Alj M, Barbu V, Fillet M, Chariot A and Bours V. NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells. ONCOGENE. 2003; 22(1):90-97.
60 Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP and Kuo ML. Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-?B-dependent XIAP Up-Regulation. J BIOL CHEM.; 279(23):24015-24023.
61 Scholzen T and Gerdes J. The Ki‐67 protein: From the known and the unknown. J CELL PHYSIOL. 2000; 182(3):311-322.